Companies across the globe are diligently working toward the development of novel treatment therapies, with a considerable amount of success over the years. Key players, such as Axsome Therapeutics, Achieve Life Sciences, Chronic Airway Therapeutics, etc., are developing therapies for the treatment of Smoking Cessation.
DelveInsight’s “Smoking Cessation Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Smoking Cessation market size, share, and trends in the seven major markets (7MM) (i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan).
The Smoking Cessation market report covers emerging drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Smoking Cessation: An Overview
Smoking cessation is the process of discontinuing tobacco smoking. When a person smokes tobacco in cigarettes, cigars, or pipes, they absorb toxins that can lead to various health problems such as diabetes, cancer, chronic obstructive pulmonary disease (COPD), heart disease, lung diseases, etc.
The main barrier to smoking cessation is nicotine addiction. Some of the most common nicotine withdrawal symptoms smokers face when they try to quit smoking include craving for smoking, mood swings, insomnia, constipation, increased appetite, anxiety, etc. Smoking cessation medicines can help lessen the craving for tobacco, decrease withdrawal symptoms, and Keep them from starting to use tobacco again
Smoking Cessation Market Key Facts
As per DelveInsight analysts, the total diagnosed prevalent cases of Smoking Cessation in the 7MM was 50,899,000+ in 2022.
Among the EU4 and the UK, Germany had the highest diagnosed prevalent cases of smokers with 19,480,000+ cases, followed by France with 13,938,000+ cases. On the other hand, the United Kingdom had the lowest diagnosed prevalent cases of 7,510,000+ in 2022.
The United States showed the highest diagnosed prevalent cases of smokers, as compared to EU4 and the UK, and Japan.
In 2022, the number of smokers in the US was estimated to be 34,134,000+.
Generally, men tend to use all tobacco products at higher rates than women. In 2022, there were 18,671,000+ diagnosed prevalent cases of smokers among males and 15,463,000+ diagnosed prevalent cases among females in the US.
Japan had 17,999,000+ diagnosed prevalent cases in 2022.
The market outlook section of the report helps to build a detailed comprehension of the historical, current and forecasted Smoking Cessation market size by analyzing the impact of current and emerging pipeline therapies. It also thoroughly assesses the market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.
The report gives complete detail of the Smoking Cessation market trend for each marketed drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MoA), Route of Administration (RoA), molecule types, competition with other therapies, brand value, and their impact on the market.
Smoking Cessation Epidemiology Assessment
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pools, future trends, and views of key opinion leaders.
The Report Covers the Smoking Cessation Epidemiology Segmented by –
Total Diagnosed Prevalent Cases of Smokers in the 7MM [2019–2032]
Gender-specific Diagnosed Prevalent Cases of Smokers in the 7MM [2019–2032]
Age-specific Diagnosed Prevalent Cases of Smokers in the 7MM [2019–2032]
Total Diagnosed Prevalent Cases of Smoking Cessation in the 7MM [2019–2032]
Smoking Cessation Drugs Uptake and Pipeline Development Activities
The drugs' uptake section focuses on the rate of uptake of the potential drugs recently launched in the Smoking Cessation market or expected to get launched during the study period. The analysis covers the Smoking Cessation market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share. The report also covers the Smoking Cessation Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Explore More About the Pipeline Development Activities @
Smoking Cessation Therapeutics Analysis
Several major pharma and biotech giants are developing therapies for Smoking Cessation. Currently, Embera NeuroTherapeutics, Inc. is leading the therapeutics market with its Smoking Cessation drug candidates in the most advanced stage of clinical development.
Therapies such as AXS-05, Cytisinicline (Cytisine), and NFL-101 are expected to enter the market during the forecasted period (2022–2032). Cytisine has been used as a smoking cessation treatment in several Central and Eastern European countries since the 1960s, is inexpensive compared to other cessation medications, and has few known side effects. With different forms, Cytisinicline is expected to enter the US market by 2023.
Some of the Leading Companies in the Smoking Cessation Therapeutics Market Include:
Achieve Life Sciences
Chronic Airway Therapeutics
Embera NeuroTherapeutics, Inc.
Smoke-Free Therapeutics (NFL Biosciences SAS)
And many others
Smoking Cessation Therapies Covered in the Report Include:
EMB-001: Embera NeuroTherapeutics, Inc.
SBP 9330: Camino Pharma
AXS-05: Axsome Therapeutics
Varenicline (Chantix/Champix): Pfizer
And many more
Learn more about the Smoking Cessation Emerging Therapies and Key Companies
Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Smoking Cessation Competitive Intelligence Analysis
4. Smoking Cessation Market Overview at a Glance
5. Disease Background and Overview
6. Smoking Cessation Patient Journey
7. Smoking Cessation Epidemiology and Patient Population (In the US, EU5, and Japan)
8. Smoking Cessation Treatment Algorithm, Current Treatment, and Medical Practices
9. Smoking Cessation Unmet Needs
10. Key Endpoints of Smoking Cessation Treatment
11. Smoking Cessation Marketed Products
12. Smoking Cessation Emerging Drugs and Latest Therapeutic Advances
13. Smoking Cessation Seven Major Market Analysis
14. Attribute Analysis
15. Smoking Cessation Market Outlook (In US, EU5, and Japan)
16. Smoking Cessation Access and Reimbursement Overview
17. KOL Views on the Smoking Cessation Market
18. Smoking Cessation Market Drivers
19. Smoking Cessation Market Barriers
21. DelveInsight Capabilities
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Download Sample PDF to Explore the Key Offerings of the Report:
Connect with us and discover how Delveinsight can help you to identify your potential business partners and investors in the highly dynamic healthcare market today @ Healthcare Partner Identification Solutions
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Address:304 S. Jones Blvd #2432
City: Las Vegas
Country: United States